固定剂量复方卡泊三醇/倍他米松泡沫剂对银屑病患者工作生产力的影响:52周随机双盲PSO-LONG试验结果
PSO-LONG试验的事后分析评估固定剂量复方卡泊三醇50微克/克/二丙酸倍他米松0.5毫克/克泡沫剂治疗4周及52周长期管理对银屑病患者工作生产力与活动损害的影响。结果显示治疗4周即显著改善银屑病相关工作出勤主义、总工作生产力损害和总活动损害,并持续至56周,可能带来可观的间接成本节省。
要点
- 固定剂量复方卡泊三醇/倍他米松泡沫剂治疗4周即显著降低银屑病相关工作出勤主义、总工作生产力损害和总活动损害。
- 上述改善在56周观察期内持续存在,且报告工作生产力及活动受损的患者比例下降。
- 工作生产力改善被转换为意大利、瑞典、英国、加拿大和德国的月度及年度间接成本节省估计。
核心结论
- 固定剂量复方卡泊三醇/倍他米松泡沫剂用于银屑病长期管理可显著减少银屑病相关工作生产力损害和活动损害,可能带来可观的间接成本节省。
研究设计与样本
- PSO-LONG试验的事后分析:一项3期、随机、双盲、载体对照、平行组、国际多中心试验,评估固定剂量复方卡泊三醇50微克/克/二丙酸倍他米松0.5毫克/克泡沫剂治疗。
- 在基线、第4周、第28周和第56周使用皮肤病生活质量指数(DLQI)和银屑病工作生产力与活动损害(WPAI:PSO)问卷评估银屑病所致工作和活动损害。
- 将工作生产力改善的小时数转换为意大利、瑞典、英国、加拿大和德国患者的月度及年度间接成本节省估计。
主要发现
- 使用固定剂量复方卡泊三醇/倍他米松泡沫剂4周在56周内显著降低银屑病相关工作出勤主义、总工作生产力损害(TWPI)和总活动损害(TAI),早在基线访视后4周即观察到显著改善。
- 报告工作生产力受影响(以出勤主义和TWPI衡量)和活动损害(以DLQI-Q7b和TAI衡量)的患者比例也下降。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Psoriasis contributes to unemployment, work impairment, missed workdays and substantial indirect costs due to lost productivity. Combination Cal/BD foam is the only topical that is approved for long-term maintenance treatment of plaque psoriasis for 52 weeks. This is the first known investigation of the effect of topical psoriasis therapy on productivity. OBJECTIVE: To examine the change in work productivity and activity impairment after 4 weeks of treatment with fixed-dose combination calcipotriol 50 µg/g/betamethasone dipropionate 0.5 mg/g (Cal/BD) foam and observe long-term changes after 52 weeks of long-term management (proactive or reactive treatment). METHODS: This is a post-hoc analysis of the PSO-LONG trial - a phase 3, randomized, double-blind, vehicle-controlled, parallel group, international multi-centre trial of treatment with combination Cal/BD foam. Work and activity impairment due to psoriasis were assessed by the Dermatology Life Quality Index (DLQI) and the Work Productivity and Activity Impairment Psoriasis (WPAI:PSO) questionnaire at baseline, week 4, week 28 and week 56. The improvement in hours of work productivity was translated into monthly and annual indirect cost savings estimates for patients in Italy, Sweden, United Kingdom, Canada and Germany. RESULTS: Using fixed-dose combination Cal/BD foam for four weeks significantly reduced psoriasis-related work presenteeism, total work productivity impairment (TWPI) and total activity impairment (TAI) over 56 weeks, with significant improvements observed as early as 4 weeks after the baseline visit. The proportion of patients reporting impact on work productivity (as measured by presenteeism and TWPI) and activity impairment (as measured by both DLQI-Q7b and TAI) also decreased. CONCLUSION: Fixed-dose combination Cal/BD foam used for long-term management of psoriasis significantly reduces psoriasis-related work productivity and activity impairment which may result in substantial indirect cost savings. Clinical Trial Registration NCT02899962, EudraCT number: 2016-000556-95.
引用
- Guenther L, Takhar A, Megna M, et al. Impact of fixed-dose combination Cal/BD foam on the work productivity of patients with psoriasis: results from the 52-week randomized, double-blind, PSO-LONG trial. J Eur Acad Dermatol Venereol. 2022. PMID: 35297108. doi:10.1111/jdv.18053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。